Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
作者信息
Potosky Arnold L, Malin Jennifer L, Kim Benjamin, Chrischilles Elizabeth A, Weeks Jane C
出版信息
J Natl Cancer Inst. 2011 Dec 21;103(24):1899-901; author reply 1901-3. doi: 10.1093/jnci/djr439. Epub 2011 Oct 28.
Abstract
摘要
相似文献
1
Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.关于：个性化医疗与癌症支持治疗：化疗中集落刺激因子支持的合理应用。
J Natl Cancer Inst. 2011 Dec 21;103(24):1899-901; author reply 1901-3. doi: 10.1093/jnci/djr439. Epub 2011 Oct 28.
2
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.个性化医疗与癌症支持性护理：化疗中集落刺激因子支持的合理应用。
J Natl Cancer Inst. 2011 Jun 22;103(12):910-3. doi: 10.1093/jnci/djr195. Epub 2011 Jun 13.
3
Under-dosing study raises questions about ways to improve regimen adherence.剂量不足研究引发了关于改善治疗方案依从性方法的问题。
J Natl Cancer Inst. 2004 Aug 18;96(16):1201-2. doi: 10.1093/jnci/96.16.1201.
4
The importance of prophylactic management of chemotherapy-induced neutropenia.
Anticancer Drugs. 2003 Oct;14(9):725-30. doi: 10.1097/00001813-200310000-00006.
5
Myeloid growth factor therapy for prophylaxis of febrile neutropenia in non-myeloid malignancies: appropriate doses and schedules.用于预防非髓系恶性肿瘤患者发热性中性粒细胞减少症的髓系生长因子治疗：合适的剂量和给药方案。
J Natl Compr Canc Netw. 2007 Feb;5(2):229-34. doi: 10.6004/jnccn.2007.0022.
6
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.化疗联合使用集落刺激因子：节省成本和改善预后的机会。
J Natl Cancer Inst. 2011 Jun 22;103(12):979-82. doi: 10.1093/jnci/djr152. Epub 2011 Jun 13.
7
Colony-stimulating factors for the management of neutropenia in cancer patients.用于癌症患者中性粒细胞减少症管理的集落刺激因子。
Drugs. 2002;62 Suppl 1:1-15. doi: 10.2165/00003495-200262001-00001.
8
Myeloid growth factors.髓系生长因子
J Natl Compr Canc Netw. 2011 Aug 1;9(8):914-32. doi: 10.6004/jnccn.2011.0075.
9
Colony-stimulating factors for adjunctive therapy of infections in neutropenic cancer patients.集落刺激因子用于中性粒细胞减少的癌症患者感染的辅助治疗
Support Care Cancer. 1995 Jan;3(1):84-5. doi: 10.1007/BF00343927.
10
Chemotherapy-induced neutropenia: new approaches to an old problem.化疗引起的中性粒细胞减少症：解决老问题的新方法。
Semin Oncol. 2003 Aug;30(4 Suppl 13):1-2. doi: 10.1016/s0093-7754(03)00313-0.
本文引用的文献
1
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.化疗联合使用集落刺激因子：节省成本和改善预后的机会。
J Natl Cancer Inst. 2011 Jun 22;103(12):979-82. doi: 10.1093/jnci/djr152. Epub 2011 Jun 13.
2
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.个性化医疗与癌症支持性护理：化疗中集落刺激因子支持的合理应用。
J Natl Cancer Inst. 2011 Jun 22;103(12):910-3. doi: 10.1093/jnci/djr195. Epub 2011 Jun 13.
3
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.2010 年版 EORTC 指南更新：粒细胞集落刺激因子在降低淋巴增殖性疾病和实体瘤成人患者化疗所致发热性中性粒细胞减少症发生率中的应用
Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20.
4
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.辅助化疗在 III 期结肠癌老年患者中的应用及不良反应。
JAMA. 2010 Mar 17;303(11):1037-45. doi: 10.1001/jama.2010.272.
5
Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer.开发和验证一个预测模型，用于预测老年乳腺癌、肺癌、结直肠癌和前列腺癌患者化疗第一周期中发热性中性粒细胞减少症的风险。
Support Care Cancer. 2011 Mar;19(3):333-41. doi: 10.1007/s00520-010-0821-1. Epub 2010 Feb 24.
6
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.老年接受化疗的晚期非小细胞肺癌患者的不良反应。
J Clin Oncol. 2010 Feb 1;28(4):620-7. doi: 10.1200/JCO.2009.23.8485. Epub 2009 Dec 28.
7
Are guidelines on use of colony-stimulating factors in solid cancers flawed?实体癌中使用集落刺激因子的指南存在缺陷吗？
Intern Med J. 2009 Apr;39(4):259-62. doi: 10.1111/j.1445-5994.2009.01899.x.
8
Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.一项多中心随机开放标签III期研究，比较传统卡铂联合依托泊苷与剂量强化卡铂联合依托泊苷加来格司亭在“广泛期”小细胞肺癌中的疗效、安全性和耐受性。
Am J Clin Oncol. 2009 Feb;32(1):61-4. doi: 10.1097/COC.0b013e31817be954.
9
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.用于预防恶性淋巴瘤治疗中不良反应的粒细胞生成刺激因子。
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003189. doi: 10.1002/14651858.CD003189.pub4.
10
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.一项使用粒细胞集落刺激因子维持非霍奇金淋巴瘤化疗剂量强度的随机对照试验长期随访后的死亡率模式
Br J Cancer. 2008 Jul 22;99(2):253-8. doi: 10.1038/sj.bjc.6604468. Epub 2008 Jul 1.
Zotero 插件